115 related articles for article (PubMed ID: 28776077)
1. Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect.
Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Molnár L; McDermott J; Zann V; Church A; Mair S; Filipcsei G; Heltovics G; Glavinas H
Cancer Chemother Pharmacol; 2017 Oct; 80(4):723-728. PubMed ID: 28776077
[TBL] [Abstract][Full Text] [Related]
2. Bioequivalence, food effect and comparative pharmacokinetics of SUVN-1105, a novel granule formulation of abiraterone acetate, to Zytiga in healthy male subjects.
Nirogi R; Ravula J; Benade V; Goyal VK; Pandey SK; Dogiparti D; Jayarajan P; Kalaikadhiban I; Jetta S; Palacharla VRC
Cancer Chemother Pharmacol; 2024 Mar; 93(3):253-264. PubMed ID: 38157042
[TBL] [Abstract][Full Text] [Related]
3. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate.
Schultz HB; Meola TR; Thomas N; Prestidge CA
Int J Pharm; 2020 Mar; 577():119069. PubMed ID: 31981706
[TBL] [Abstract][Full Text] [Related]
4. Bioavailability Enhancement and Food Effect Elimination of Abiraterone Acetate by Encapsulation in Surfactant-Enriched Oil Marbles.
Boleslavská T; Rychecký O; Krov M; Žvátora P; Dammer O; Beránek J; Kozlík P; Křížek T; Hořínková J; Ryšánek P; Roušarová J; Canová NK; Šíma M; Slanař O; Štěpánek F
AAPS J; 2020 Sep; 22(6):122. PubMed ID: 32978690
[TBL] [Abstract][Full Text] [Related]
5. Development of an abiraterone acetate formulation with improved oral bioavailability guided by absorption modeling based on in vitro dissolution and permeability measurements.
Solymosi T; Ötvös Z; Angi R; Ordasi B; Jordán T; Semsey S; Molnár L; Ránky S; Filipcsei G; Heltovics G; Glavinas H
Int J Pharm; 2017 Oct; 532(1):427-434. PubMed ID: 28919099
[TBL] [Abstract][Full Text] [Related]
6. Investigations of the mechanism behind the rapid absorption of nano-amorphous abiraterone acetate.
Basa-Dénes O; Solymosi T; Ötvös Z; Angi R; Ujhelyi A; Jordán T; Heltovics G; Glavinas H
Eur J Pharm Sci; 2019 Mar; 129():79-86. PubMed ID: 30610953
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two Randomized, Open-Label, Crossover Studies.
Goldwater R; Hussaini A; Bosch B; Nemeth P
Clin Pharmacokinet; 2017 Jul; 56(7):803-813. PubMed ID: 28425029
[TBL] [Abstract][Full Text] [Related]
8. Open-Label, Phase I, Pharmacokinetic Studies in Healthy Chinese Subjects to Evaluate the Bioequivalence and Food Effect of a Novel Formulation of Abiraterone Acetate Tablets.
Feng Z; Liu Y; Kuang Y; Yang S; Li J; Ye L; Huang J; Pei Q; Huang Y; Yang G
Drug Des Devel Ther; 2022; 16():3-12. PubMed ID: 35018094
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
Jenner P; Könen-Bergmann M; Schepers C; Haertter S
Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
[TBL] [Abstract][Full Text] [Related]
10. A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics.
Lubberman FJE; Benoist GE; Gerritsen W; Burger DM; Mehra N; Hamberg P; van Oort I; van Erp NP
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1179-1185. PubMed ID: 31515667
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man.
Geboers S; Stappaerts J; Mols R; Snoeys J; Tack J; Annaert P; Augustijns P
J Pharm Sci; 2016 Sep; 105(9):2974-2981. PubMed ID: 27061460
[TBL] [Abstract][Full Text] [Related]
12. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer.
Chi KN; Spratlin J; Kollmannsberger C; North S; Pankras C; Gonzalez M; Bernard A; Stieltjes H; Peng L; Jiao J; Acharya M; Kheoh T; Griffin TW; Yu MK; Chien C; Tran NP
J Clin Pharmacol; 2015 Dec; 55(12):1406-14. PubMed ID: 26096139
[TBL] [Abstract][Full Text] [Related]
13. Dose Finding and Food Effect Studies of a Novel Abiraterone Acetate Formulation for Oral Suspension in Comparison to a Reference Formulation in Healthy Male Subjects.
Jordán T; Basa-Dénes O; Angi R; Orosz J; Ötvös Z; Ujhelyi A; Filipcsei G; Molnár L; Solymosi T; Glavinas H; Capone D; Whitfield N; McDermott J; McKenzie L; Shurety L; Duus EM
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959452
[TBL] [Abstract][Full Text] [Related]
14. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin.
Chandra R; Liu P; Breen JD; Fisher J; Xie C; LaBadie R; Benner RJ; Benincosa LJ; Sharma A
Clin Pharmacokinet; 2007; 46(3):247-59. PubMed ID: 17328583
[TBL] [Abstract][Full Text] [Related]
16. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
17. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
18. Supersaturated-Silica Lipid Hybrids Improve in Vitro Solubilization of Abiraterone Acetate.
Schultz HB; Joyce P; Thomas N; Prestidge CA
Pharm Res; 2020 Mar; 37(4):77. PubMed ID: 32236761
[TBL] [Abstract][Full Text] [Related]
19. Development, Characterization, and Optimization of a Novel Abiraterone Acetate Formulation to Improve Biopharmaceutical Attributes Aided by Pharmacokinetic Modelling.
Dahiya S; Savjani K; Savjani J
AAPS PharmSciTech; 2021 Nov; 23(1):4. PubMed ID: 34811624
[TBL] [Abstract][Full Text] [Related]
20. Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate.
Hussaini A; Olszanski AJ; Stein CA; Bosch B; Nemeth P
Cancer Chemother Pharmacol; 2017 Sep; 80(3):479-486. PubMed ID: 28695267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
